Science1 min read

Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%

By · Via Ars Technica · Published by Everything Blog

In short

Moderna and Merck's mRNA cancer vaccine demonstrated a 42% reduction in death and recurrence rates, indicating promising outcomes for patients and a positive impact on their care.

Key points

  • The vaccine's effectiveness is significant, reducing death and recurrence by 42%.: The vaccine's effectiveness is significant, reducing death and recurrence by 42%.
  • The study results suggest a positive impact on patient care.: The study results suggest a positive impact on patient care.
  • The findings are promising for patients and could lead to better outcomes.: The findings are promising for patients and could lead to better outcomes.

Markers released top-line results today after previously reporting the trial succeeded.

Original source: arstechnica.com

Science